Cost-Effective Theraputics

Technology Partners has a long history of investing in cost-effective therapeutics dating back to our first investment in Ventritex in 1986. Cost pressures on the healthcare system will accelerate as baby boomers hit their peak healthcare consumption years. Therefore, effective therapeutic products that can replace costly services and procedures will continue to be a compelling area in which to invest.




Cost-Effective Theraputics Portfolio
 

Calypte Biomedical (AMEX: HIV)
Calypte Biomedical Corporation is a provider of diagnostic testing solutions for HIV, STDs, and other chronic diseases.

     
 

Cell Pathways
Acquired by OSI Pharmaceuticals (NASDAQ: OSIP)
Cell Pathways (formerly NASDAQ: CLPA) developed drugs that induce selective apoptosis (programmed cell death) in precancerous and cancerous cells for the prevention and treatment of colon and lung cancers.

     
 

CryoCor (NASDAQ: CRYO)
CryoCor (formerly NASDAQ: CRYO) is developing cryo-ablation devices for the minimally invasive treatment of atrial fibrillation and other cardiac arrhythmias.

     
 

Epigenesis Pharmaceuticals
Epigenesis Pharmaceuticals is developing novel products for respiratory diseases. 

     
  HeartStent
Acquired by Percardia
     
  Medwave (NASDAQ: MDWV) Medwave manufactures and markets a non-invasive monitoring system for measuring blood pressure.
     
  Acquired by St. Jude Medical
(NYSE: STJ)
Ventritex (formerly NASDAQ: VNTX) was a pioneer in the development of implantable defibrillators for the treatment of ventricular tachycardia and fibrillation.


Copyright 2008© Technology Partners. All rights reserved. SITE MAP